Medical researchers have revealed a possible underlying genetic pathway behind the neurological dysfunction of Rett syndrome. The team found that deficiencies in key genes involved in the pathology triggers neural stem cells to generate less neurons by producing more astrocytes--the brain's maintenance cells.
The researchers hope that the molecular pathology they identified, as reported in the journal Cell Reports, can lead to potential therapeutic targets for Rett syndrome in the future.
Rett syndrome is a progressive neurodevelopmental disorder characterized by impairments in cognition and coordination--with varying severity--and occurs in roughly one in every 10,000 to 15,000 female births. However, it is difficult to initially identify because children appear to develop normally in the first 6-18 months.
"Rett syndrome is caused by mutations in a single gene called methyl-CpG binding protein 2, or MeCP2. The gene was identified over two decades ago and much has been uncovered since, but exactly how the mutations cause the pathology remains elusive," explains first author.
In their past research, the team had identified that MeCP2 acts as a regulator for the processing of specific microRNAs to control the functions of neurons. So, they went back to investigate if that pathway was also involved in the differentiation of neural stem cells.
Compared to messenger RNA, the final template transcribed from DNA that is used by a cell to synthesize proteins, microRNAs--or miRNAs--are much smaller and act to regulate messenger RNA to make sure the cell is making the correct amount of the desired protein.
"Through our investigation, we found several microRNAs associated with MeCP2, but only one affected the differentiation of neural stem cells: a microRNA called miR-199a," says the author. "In fact, when either MeCP2 or miR-199a are disrupted, we found that it increased the production of cells called astrocytes."
Astrocytes are like the support cells of your brain. While neurons fire off the electrical signals, astrocytes are there to help maintain everything else. During development, astrocytes and neurons are generated from the same type of stem cells, known as neural stem cells, where their production is carefully controlled. However, dysfunction in MeCP2 or miR-199a causes these stem cells to produce more astrocytes than neurons.
"Further analysis showed that miR-199a targets the protein Smad1, a transcription factor critical for proper cellular development. Smad1 functions downstream of a pathway called BMP signaling, which is known to inhibit the production of neurons and facilitate the generation of astrocytes," states the author.
To investigate the process further, the team established a brain organoid culture--a 3D culture of neural stem cells that can mimic aspects of brain development--from iPS cells derived from patients with Rett syndrome. When they inhibited BMP, short for bone morphogenetic protein, the team was able to reduce abnormal neural stem cell differentiation.
"Our findings have given us valuable insight into the role of MeCP2, miR-199a, and BMP signaling in the pathology of Rett syndrome," concludes the author. "Further investigation is needed, but we hope this can lead to clinical treatments for Rett syndrome symptoms."
https://www.kyushu-u.ac.jp/en/researches/view/214
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00463-0
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fmecp2-controls-neural&filter=22
Gene dysfunction produces more astrocytes than neurons in Rett syndrome
- 1,915 views
- Added
Edited
Latest News
Circadian rhythms can influ…
By newseditor
Posted 27 Apr
With hybrid brains, these m…
By newseditor
Posted 27 Apr
Blocking activation of NF-κ…
By newseditor
Posted 27 Apr
Vitamin D regulates microbi…
By newseditor
Posted 27 Apr
Role of alternative splicin…
By newseditor
Posted 27 Apr
Other Top Stories
Taste center of the human brain!
Read more
Inactive ingredients in pills and capsules may cause allergic, adve…
Read more
Two-drug combos using popular calcium channel blocker show superior…
In the largest randomized controlled trial of treatment for high blood pressure ever conducted in sub-Saharan Africa, two frontline two-drug combinations that included the long-acting calcium channel blocker, amlodipine, were able to drive down blood pressure levels more than a third two-drug combination that did not include amlodipine, according to research presented at the American College…
Read more
The brain pathway responsible for alcohol cravings
Read more
Diet sodas linked to increased risk of stroke in women over 50
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Single dose creatine improv…
By newseditor
Posted 27 Apr
Autonomous circadian rhythm…
By newseditor
Posted 27 Apr
Functional sensory circuits…
By newseditor
Posted 27 Apr
Positive selection CRISPR s…
By newseditor
Posted 27 Apr
Focal clusters of peri-syna…
By newseditor
Posted 27 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar